SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q2 2023 vs. Q1 2023
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 39 | 38 | −1 |
| Shares | 3.87M | 3.96M | +87.8K (+2.3%) |
| Value | $1.71M | $3.28M | +$1.58M (+92.2%) |
New holders (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 54,400 | $45.0K | 0.00% |
| Peapack Gladstone Financial Corp | 52,296 | $43.0K | 0.00% |
| Prudential Financial Inc | 36,200 | $30.0K | 0.00% |
| Two Sigma Investments, LP | 25,094 | $20.8K | 0.00% |
Sold out (5)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Warberg Asset Management LLC | 177,659 | $78.2K |
| Meteora Capital, LLC | 134,524 | $59.2K |
| Citadel Advisors LLC | 28,400 | $12.5K |
| UBS Group AG | 6,679 | $2.94K |
| Barclays PLC | 54 | $24 |